Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.AORT · Entity 4767 | President & CEO | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 877,275 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 70,000 · Balance 877,275 F1: Reflects weighted average price. Range of prices were between $28.89 to $29.15. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects weighted average price. Range of prices were between $28.89 to $29.15. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 1
1 source rowRow 1 · 2020-11-11 · Other · Disposed 11,720 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 11,720 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement) |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 11,720 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement)
F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 20, 2026 18:11 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 70,000 | $28.96 | $2,026,850.00 |
DisclosureSEC source: 0001628280-26-058212 · wk-form4_1787249462.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 877,275 F1 · price: Reflects weighted average price. Range of prices were between $28.89 to $29.15. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 23:44 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 17,887 | $37.78 | $675,692.16 |
DisclosureSEC source: 0001628280-26-014887 · wk-form4_1772667862.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 947,275 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 20:02 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 14,911 | $38.02 | $566,989.28 |
DisclosureSEC source: 0001628280-26-013684 · wk-form4_1772568129.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848,214 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:44 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 116,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014887 · wk-form4_1772667862.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965,162 F1 · shares: Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:34 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 97,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011831 · wk-form4_1772058879.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,125 F3 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:34 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,936 | $35.69 | $497,417.65 |
DisclosureSEC source: 0001628280-26-011831 · wk-form4_1772058879.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,095 F2 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:34 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 20,962 | $37.59 | $787,919.66 |
DisclosureSEC source: 0001628280-26-011831 · wk-form4_1772058879.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,031 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 30,921 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · derivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,921 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 30,921 | $45.46 | $1,405,699.58 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800,993 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2 · price: Reflects weighted average price. Range of prices were between $45.09 to $45.91. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 01:54 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 30,921 | $29.62 | $915,880.02 |
DisclosureSEC source: 0001628280-25-055466 · wk-form4_1764899693.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 831,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 30,921 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · derivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,921 shares Expires 2026-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 5, 2020. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 30,921 | $45.56 | $1,408,729.84 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800,993 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2 · price: Reflects weighted average price. Range of prices were between $45.25 to $46.09. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 00:27 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 30,921 | $29.62 | $915,880.02 |
DisclosureSEC source: 0001628280-25-055181 · wk-form4_1764808042.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 831,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 17:09 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 34,210 | $45.86 | $1,568,802.18 |
DisclosureSEC source: 0001628280-25-052264 · wk-form4_1763140154.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,993 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 01:08 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 17,580 | $44.62 | $784,402.02 |
DisclosureSEC source: 0001628280-25-051795 · wk-form4_1762996112.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,203 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 15:28 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 12,500 | $42.32 | $528,987.50 |
DisclosureSEC source: 0001408470-25-000003 · wk-form4_1755617286.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 852,783 F1 · price: Reflects weighted average price. Range of prices were between $42.25 to $42.585. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:18 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 75,615 | $0.00 Strike: $21.55 | $0.00 |
DisclosureSEC source: 0000784199-25-000057 · wk-form4_1741641526.xml · derivative · entry 5 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,615 shares Expires 2025-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was March 12, 2019. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:18 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 70,700 | $24.76 | $1,750,843.08 |
DisclosureSEC source: 0000784199-25-000057 · wk-form4_1741641526.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 865,283 F3 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 30, 2024. F4 · price: Reflects weighted average price. Range of prices were between $24.40 to $25.10. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:18 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 75,615 | $21.55 | $1,629,503.25 |
DisclosureSEC source: 0000784199-25-000057 · wk-form4_1741641526.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 935,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 30, 2024. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:18 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 17,739 | $24.80 | $440,005.25 |
DisclosureSEC source: 0000784199-25-000057 · wk-form4_1741641526.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 860,368 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:18 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 115,701 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000057 · wk-form4_1741641526.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 878,107 F1 · shares: Represents performance stock units granted on February 23, 2024. One third (1/3) were issued on March 6, 2025. The remaining shares earned in connection with the February 2024 grant will be eligible to vest and be issued as follows: one third (1/3) on February 23, 2026; and one third (1/3) on February 23, 2027, assuming employment on the relevant vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 20:06 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 98,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000039 · wk-form4_1741118781.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,406 F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 19:00 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 4,896 | $27.31 | $133,690.18 |
DisclosureSEC source: 0000784199-25-000022 · wk-form4_1740596426.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,882 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 19:00 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 6,812 | $27.31 | $186,008.47 |
DisclosureSEC source: 0000784199-25-000022 · wk-form4_1740596426.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,778 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 19:00 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,784 | $27.31 | $376,385.90 |
DisclosureSEC source: 0000784199-25-000022 · wk-form4_1740596426.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,590 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 19:00 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 16,664 | $27.31 | $455,027.18 |
DisclosureSEC source: 0000784199-25-000022 · wk-form4_1740596426.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,374 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:20 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,996 | $18.72 | $262,037.31 |
DisclosureSEC source: 0000784199-24-000108 · wk-form4_1709853614.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,562 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 05, 2024 Filed Mar 14, 2024 23:45 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,996 | $18.72 | $262,037.31 |
DisclosureSEC source: 0000784199-24-000110 · wk-form4a_1710459906.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,038 F3 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary transaction. F2 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| March 01, 2024 Filed Mar 7, 2024 23:20 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 28,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000108 · wk-form4_1709853614.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,558 F1 · shares: Represents LTIP performance stock units of which one hundred percent (100%) were issued on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 14, 2024 23:45 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 28,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000110 · wk-form4a_1710459906.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,034 F1 · shares: Represents LTIP performance stock units of which one hundred percent (100%) were issued on March 1, 2024. F2 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:36 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 4,837 | $19.83 | $95,939.48 |
DisclosureSEC source: 0000784199-24-000088 · wk-form4_1709246193.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,940 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 27, 2024 Filed Mar 14, 2024 23:57 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 4,837 | $19.83 | $95,938.99 |
DisclosureSEC source: 0000784199-24-000120 · wk-form4a_1710460668.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,416 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary transaction. F2 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,168 | $20.27 | $266,929.84 |
DisclosureSEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,777 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 18,144 | $20.27 | $367,798.84 |
DisclosureSEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,297 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 26, 2024 Filed Mar 15, 2024 00:14 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 12,968 | $20.27 | $262,875.62 |
DisclosureSEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,253 F5 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 13,168 shares were sold, when in fact, 12,968 shares were sold. F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 26, 2024 Filed Mar 15, 2024 00:14 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 17,868 | $20.27 | $362,204.01 |
DisclosureSEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,573 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 18,144 shares were sold, when in fact, 17,868 shares were sold. F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 22:55 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 89,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000043 · wk-form4_1708988118.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,037 F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 22:22 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 58,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,945 F3 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 22:22 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 40,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000072 · wk-form4_1709158886.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,441 F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024. Read SEC document |
| February 23, 2024 Filed Mar 15, 2024 00:14 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 58,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 709,221 F4 · shares: Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date. F3 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 23, 2024 Filed Mar 15, 2024 00:14 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 40,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000134 · wk-form4a_1710461680.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,441 F1 · shares: Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Option(Right to Buy) · Derivative | 59,225 | $0.00 Strike: $16.30 | $0.00 |
DisclosureSEC source: 0000784199-24-000016 · wk-form4_1708639663.xml · derivative · entry 5 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,225 shares Expires 2024-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 02/21/2018. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,756 | $18.87 | $51,991.94 |
DisclosureSEC source: 0000784199-24-000016 · wk-form4_1708639663.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,036 F4 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 10,088 | $18.87 | $190,310.12 |
DisclosureSEC source: 0000784199-24-000016 · wk-form4_1708639663.xml · nonDerivative · entry 3 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,792 F3 · shares: These shares were sold upon the vesting of Restricted Stock awards to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 59,225 | $18.85 | $1,116,515.62 |
DisclosureSEC source: 0000784199-24-000016 · wk-form4_1708639663.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,880 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2023. F2 · price: Reflects weighted average price. Range of prices were between $18.05 to $19.295. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 59,225 | $16.30 | $965,367.50 |
DisclosureSEC source: 0000784199-24-000016 · wk-form4_1708639663.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2023. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 23:07 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 9,990 | $13.41 | $133,983.88 |
DisclosureSEC source: 0000784199-23-000072 · wf-form4_167788481957790.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,880 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:07 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 21,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-23-000072 · wf-form4_167788481957790.xml · nonDerivative · entry 1 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,870 F1 · shares: Represents LTIP performance stock units of which hundred percent (100%) were issued on March 1, 2023. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:36 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 9,985 | $12.94 | $129,185.93 |
DisclosureSEC source: 0000784199-23-000048 · wf-form4_167771379285071.xml · nonDerivative · entry 4 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,052 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:36 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 12,645 | $12.94 | $163,601.01 |
DisclosureSEC source: 0000784199-23-000048 · wf-form4_167771379285071.xml · nonDerivative · entry 2 Mackin James P · CIK 0001408470 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,889 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.